[ad_1]
KFAR-SABA, Israel – ( BUSINESS WIRE ) – CathWorks has announced the approval of a new CPT code 0523T for
non-invasive, 3D FFRangio ™ permissible interpretation of possible
Atherosclerotic stenosis during coronary angiography procedures. the
the code show is a big step forward to help the doctors objectively
and cost-effectively determine if PCI (percutaneous coronary
intervention) is indicated and revascularization has occurred in
coronary angiography procedure.
This breakthrough in objective intraprocedural decision-making is made
possible through the development of the CathWorks FFRangio ™ system. It is the
non-invasive FFR platform that provides fast and accurately objective
multi-vessel physiological measurements to optimize and make profitable
confirm intraprocedural PCI treatment decisions.
Code CPT 0523T allows health professionals to use CathWorks
FFRangio ™ system to be reimbursed:
Intraoperative Coronary Fractional Flow Rate (FFR) with 3D
Functional mapping of color-coded FFR values for the entire coronary
tree, derived from coronary angiography data that allow a real-time examination
and interpretation of a possible intervention on atherosclerotic stenosis (s).
CathWorks CEO Jim Corbett said, "The approval of the CPT 0523T code is very
important step for our company and the market. The decision of the CPT code
also reflects the long-term clinical importance of FFR objectives
PCI Decision Making. Create a long-term repayment solution
FFRangio ™ intraprocedural support will allow physicians, patients, and
payers to realize the proven clinical and economic benefits of FFR on a
each case. "
The FFRangio ™ system from CathWorks is under development and is not yet FDA
deleted.
About CathWorks
CathWorks is a medical technology company focused on the application of its
advanced computational science platform to optimize PCI therapy
decisions and elevate the coronary angiography of visual badessment to a
objective decision making tool based on FFR for physicians. PCI guided by FFR
it has been proven that decision-making provides significant clinical benefits
patients with coronary artery disease and economic benefits for patients
and the payers. The goal of the company today is precisely to bring the
CathWorks FFRangio ™ system on the market to provide fast, accurate, and
an objective intraprocedural FFR guide, practical in all cases.
Source link
